EMD Serono
Manufacturing · Massachusetts, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1 Technology Pl, Rockland, Massachusetts...Phone Number
(800) 283-8088Website
www.emdserono.comRevenue
$758.5 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
6
1
2
1
2
About EMD Serono
At EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S., we work to transform lives by developing and delivering meaningful therapies, and working to truly understand and respond to the therapeutic and support needs of individual patients.Explore more
EMD Serono Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EMD Serono your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
EMD Serono, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at EMD Serono
Funding: Get notified immidiatlly once EMD Serono has new funding data
Click to see if EMD Serono had a recent Job posting/layoffs
Product Launch: Get notified when EMD Serono launches new products
Earning: See what the market has to say on EMD Serono recently announced quarterly report
Check out if EMD Serono is spiking on competitors!
Check if EMD Serono has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined EMD Serono as Masked Content
Find 2 more new buyers
Compare Similar Companies to EMD Serono
Compare insights from companies similar to EMD Serono, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
EMD Serono
$758.5M
1K - 5K
Private
-
1981
TE
Thorsten EickenhorstSenior Vice President and Chief Medical Officer
Company Profile Activity
Activity Insights
EMD Serono is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EMD Serono is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EMD Serono.
EMD Serono Tech Stack
A closer look at the technologies used by EMD Serono
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
EMD Serono News & Media
EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
BOSTON--(BUSINESS WIRE)--Not intended for media outside the U.S. or Canada EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-responsPimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor
BOSTON--(BUSINESS WIRE)--EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER trial evaluating pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., in the treatment of patients with tenosynovial giant cell tumor (TGCT). Once-daily pimicotinibEMD Serono Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
BOSTON--(BUSINESS WIRE)--EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare tumor TGCT, as well as data from both company-EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash
BOSTON--(BUSINESS WIRE)--Not intended for media outside the U.S. or Canada EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demonstrating clinically meaningful reduction in disease activity in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active lupus rash. The findings are from Cohort A of the Phase 2 WILLOW
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EMD Serono
Sign Up For FreeTo access detailed company insights
At EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S., we work to transform lives by developing and delivering meaningful therapies, and working to truly understand and respond to the therapeutic and support needs of individual patients.... Read More
